Octanoyl galactose ester-modified microemulsion system self-assembled by coix seed components to enhance tumor targeting and hepatoma therapy

Ding Qu^{1,2}
Mingjian Liu¹
Mengmeng Huang^{1,2}
Lixiang Wang¹
Yan Chen^{1,2}
Congyan Liu^{1,2}
Yuping Liu^{1,2}

¹Research Center for Multicomponent Traditional Medicine and Microecology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, ²Research Center for Multicomponent Traditional Medicine and Microecology, Jiangsu Provincial Academy of Traditional Chinese Medicine, Nanjing, People's Republic of China

Abstract: A nanosized drug delivery platform with a combination of rational components and tumor targeting is significant for enhancement of anticancer therapy and reduction of side effects. In this study, we developed a octanoyl galactose ester-modified microemulsion system self-assembled by coix seed components (Gal(oct)-C-MEs), which improved the tumor accumulation through asialoglycoprotein receptor-mediated endocytosis and promoted the antitumor efficacy through multicomponent-mediated synergistic effect. Octanoyl galactose ester (Gal(oct)) with a yield of 82.3% was synthesized through a green enzymatic reaction and multidimensional characterization. Gal(oct)-C-MEs with a spherical shape had a small and uniform particle size (58.49 ± 1.03 nm), narrow polydispersity index (0.09 ± 0.01) and neutral surface charge (-5.82 ± 0.57 mV). In the cellular uptake studies, the internalized Gal(oct)-C-ME was 2.28-fold higher relative to that of coix seed component-based microemulsions (C-MEs). The half-maximal inhibitory concentration of Gal(oct)-C-MEs against HepG2 cells was 46.5 ± 2.4 μ g/mL, which was notably higher than that of C-MEs. Importantly, the intratumor fluorescence of HepG2 xenograft-bearing nude mice treated with Cy5/Gal(oct)-C-MEs was 1.9-fold higher relative to treatment with Cy5/C-MEs. In the study of antitumor efficacy in vivo, HepG2 xenograft-bearing nude mice intragastrically administered Gal(oct)-C-MEs for 14 days exhibited the strongest inhibition of tumor growth and the lowest toxicity against liver and kidney among all the treatments. In summary, Gal(oct)-C-ME, as a highly effective and safe anticancer drug delivery system, showed promising potential for hepatoma therapy.

Keywords: coix seed oil, coixan, multicomponent-based microemulsion, hepatic targeting, antihepatoma, oral drug delivery system

Introduction

Hepatocellular carcinoma (HCC) is the fifth most frequently diagnosed cancer worldwide and the second and sixth leading cause of cancer death in men and women, respectively.¹ Higher incidence of HCC is reported in East Asia and sub-Saharan Africa due to the dietary habits and public hygiene.² Although chemotherapy is a most commonly used and effective approach for treatment of HCC, the severe systemic side effects resulting from nonselective biodistribution still enormously restrict the clinical applications.^{3,4} Recently, nano-sized drug delivery system (DDS) showed a promising potentiality in tumor-specific accumulation by enhanced permeability and retention (EPR) effect. For example, there are several clinically applied nanomedicines for cancer therapy, such as Doxil® (PEGylated liposomal doxorubicin [DOX], Johnson & Johnson, NJ, USA), micellar paclitaxel (PTX/NK-105) and Lipusu® (liposomal paclitaxel [PTX], Luye Pharma, Shandong, China).^{5,6} Until now, however,

Correspondence: Yan Chen
Research Center for Multicomponent Traditional Medicine and Microecology, Jiangsu Provincial Academy of Chinese Medicine, 100 Shizi Road, Nanjing, Jiangsu 210028, People's Republic of China
Tel +86 25 8560 8672
Fax +86 25 8563 7809
Email ychen202@hotmail.com

few commercial formulations have been modified with well-known tumor ligands (folic acid, cholic acid, transferrin, hyaluronic acid, etc) or exclusively designed for active tumor targeting, although the nanomedicines improved the therapeutic efficacy and reduced the adverse effects of the anticancer drugs.⁷⁻⁹ In fact, tumor-targeted, ligand-modified nanomedicines have to overcome a serious problem of the exogenous interference to tumor-specific recognition. Besides, the modification method also influences tumor targeting, because it decides the exposure destiny of tumor ligands on the surface of the nanoparticle.

As we know, galactose- and *N*-acetylgalactosamine-terminated glycoproteins have high affinity for asialoglycoprotein receptor, which is highly expressed on the surface of the hepatoma cells. Galactose-modified nanosized DDSs have increasingly become one of the most promising hepatoma-targeted nanomedicines for treatment of liver cancer.¹⁰⁻¹³ Previous publications demonstrated that the galactose-containing, fluorescein isothiocyanate (FITC)-labeled dextran-g-PCL micelles had an apparent targeting to HepG2 cells and liver tissue.¹⁴ However, such a modification

method of galactose usually needs chemical catalyzer and harsh reaction conditions. Recently, our group has developed butyryl galactose ester (Gal(but)) and stearic galactose ester (Gal(ste)) by a green enzymatic reaction method. In addition, a multicomponent microemulsion system was prepared through self-assembly of coix seed oil, coixan, RH40 and polyethylene glycol 400 (PEG400) using Gal(but) or Gal(ste) as the targeting ligand.^{15,16} Interestingly, we found that galactose ester with different lengths of chain significantly influenced the targeting on the liver and liver tumor. Sparked by this strategy, we were interested to determine whether galactose ester with medium lengths of chain probably had a better liver and hepatoma targeting.

Herein, octanoyl galactose ester with a medium length chain was synthesized and octanoyl galactose ester-modified coix seed component microemulsion (Gal(oct)-C-ME) based on coix seed oil and coixan was prepared by using a previously reported method (Figure 1). After crossing the intestinal tract, Gal(oct)-C-ME was capable of accumulating at the tumor sites by the EPR-mediated passive targeting and galactose ester-mediated active targeting, thereby enhancing the cellular uptake

Figure 1 Schematic illustration of Gal(oct)-C-MEs assembled from coix seed oil (oil phase), Coixan (passive targeting component), RH40 (surfactant), PEG400 (co-surfactant) and Gal(oct) ester (active targeting ligand).

Notes: Due to modification with medium carbon chain, the Gal segments were completely exposed outside the particles, thereby enhancing internalization by hepatoma carcinoma cells that was mediated by ligand-receptor recognition and EPR effect.

Abbreviations: ASGPR, asialoglycoprotein receptor; C-MEs, coix seed component-based microemulsions; EPR, enhanced permeability and retention; Gal(oct)-C-MEs, octanoyl galactose ester-modified microemulsion system self-assembled by coix seed components; PEG, polyethylene glycol.

and anticancer efficacy. The enhanced tumor targeting was characterized by fluorescent probe techniques and near-infrared imaging *in vivo*. The advantages of such a design were investigated through evaluation of tumor cell killing, cell apoptosis induction, *in vivo* anticancer efficacy and safety.

Materials and methods

Materials

Coix seed oil was extracted by our group using a supercritical CO₂ fluid extraction technology (purity of glycerin trilaurate >85%, determined by ultraviolet spectroscopy). Coix seed polysaccharides (Coixan) were purified using a classical water extraction and alcohol precipitation method by our group (purity >75%, determined by ultraviolet spectroscopy). Novozym 435 and 4A molecular sieve were purchased from Nanjing Cheng-Na Chemical Co., Ltd (Nanjing, People's Republic of China). Vinyl *n*-octanoate, D-galactose and PEG400 were obtained from Sigma-Aldrich (St Louis, MO, USA). Cremophor® RH40 was obtained from BASF Co., Ltd (Ludwigshafen, Germany). Roswell Park Memorial Institute 1640 medium, fetal bovine serum (FBS), penicillin–streptomycin solution and phosphate-buffered saline (PBS) were provided by Thermo Fisher Scientific Inc. (Waltham, MA, USA). 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay and Annexin V-PE assay kit were both provided by KeyGen Biotech Co., Ltd (Jiangsu, People's Republic of China). FITC and Cy5 were purchased from Tianjin Biolite Biotech Co., Ltd (Tianjin, People's Republic of China). Human hepatoma (HepG2) cells were bought from Shanghai Institute of Biochemistry and Cell Biology. Male Balb/c mice (6–8 weeks old) weighing 22–25 g were purchased from SLAC Co., Ltd (Shanghai, People's Republic of China). Water in this study was prepared by the Milli-Q-water purification system (Merck Millipore, Billerica, MA, USA). All other chemicals and solvents were of analytical grade, unless otherwise stated.

Synthesis and characterization of octanoyl galactose ester

Octanoyl galactose ester (Gal(oct)), a hepatic-targeted ligand, was synthesized by a enzymatic reaction between vinyl *n*-octanoate and D-galactose using Novozym 435 immobilized lipase as a catalyzator. Briefly, vinyl *n*-octanoate (3.0 mL, 15.5 mmol) and D-galactose (2.8 g, 15.6 mmol) were dissolved in 50 mL of dehydrated acetone in the presence of 4A molecular sieve, which was followed by addition of Novozym 435 immobilized lipase slowly. After vigorous stirring for 15 h at 60°C, the mixture was

filtered to remove the enzyme and molecular sieve, and consequently, the crude product was obtained through evaporating acetone under reduced pressure. Highly purified octanoyl galactose ester was prepared with a yield of 82.3% by using a silica gel column separation technology (100–200 mesh) with an eluent of methanol/dichloromethane (1/10, v/v). The chemical structure of the product was multidimensionally characterized, including Fourier transform infrared (FTIR) spectroscopy, hydrogen spectrum nuclear magnetic resonance (¹H NMR) and high-resolution mass spectrum (HRMS) analysis. ¹H NMR spectra were recorded on a Bruker AVANCE-300 spectrometer (300 MHz; Bruker Optik GmbH, Ettlingen, Germany) in deuterated chloroform (CDCl₃) at room temperature. Chemical shifts are reported in ppm with the internal tetramethylsilane signal at 0.0 ppm as a standard. FTIR spectra were recorded with KBr pellets on an FTIR spectrometer (Nicolet 2000; Magna IR 550; Madison, Nicolet Inc., WI, USA) at room temperature. HRMS analysis was performed using Agilent Q-TOF system (6545; Agilent Technologies, Santa Clara, CA, USA) using electrospray ionization (ESI+) model; prior to the experiment, the sample was dissolved in mass grade methanol at a concentration of 20 ng/mL.

Preparation and characterization of microemulsions

The Gal(oct)-C-MEs were prepared using “one-step” emulsion method described previously.¹⁶ Briefly, octanoyl galactose ester (32 mg), coixan (240 mg), Cremophor RH40 (150 mg) and PEG400 (50 mg) were mixed with vigorous magnetic stirring at room temperature until a completely homogeneous mixture was obtained. Afterward, coix seed oil (200 mg) was added in batches to the above-mentioned mixture, followed by stirring for another 2 h. A faint yellow transparent Gal(oct)-C-MEs solution with low viscosity was obtained on adding 2.5 mL of deionized water slowly into the mixture. Coix seed components microemulsions (C-MEs) were prepared by a similar method, but without adding octanoyl galactose ester.

The average size, polydispersity index and zeta potential of various types of microemulsions were measured in triplicate by dynamic light scattering analyzer (Nano ZS; Malvern Instruments Ltd, Malvern, UK). For the morphologic study, 30 µL of Gal(oct)-C-MEs was deposited onto a film-coated copper grid, followed by staining with 30 µL of 1.5% aqueous solution of phosphotungstic acid and observing immediately by transmission electron microscopy (JEM-200CX; JEOL, Tokyo, Japan) after air drying.

Cell culture

HepG2 cells were cultured in Roswell Park Memorial Institute 1640 medium containing 10% FBS (v/v) at 37°C under an atmosphere of 5% CO₂ and 90% relative humidity. The cells were passaged using trypsin at a split ratio of 1:8, after they reached 80% confluence.

Cellular uptake and internalization mechanism

For cellular uptake study, FITC was employed as a fluorescence probe to visualize the intracellular Gal(oct)-C-MEs and other formulations. Various types of FITC-labeled formulations were prepared using the above-mentioned method, but by adding FITC and adjusting the concentration to 2 µM. The exponential phase HepG2 cells were cultured in 24-well plates at a density of 1.0×10^5 cells per well for 24 h. After reaching 60% overspread, the culture medium was replaced with FITC-labeled formulations, followed by incubation for another 2 h. Then the cells were washed with precooling PBS thoroughly to remove the remaining fluorescence. At the end of this time, the adherent cells were immediately observed by fluorescence inverse microscope (IX73; Olympus Corporation, Tokyo, Japan). Likewise, the cell suspension harvested in 0.3 mL of PBS was also analyzed by flow cytometry (Guava 6HT, Merck Millipore).

The mechanism of cellular uptake was evaluated by pretreatment with specific inhibitors.^{17,18} When the cells grew up to 60% confluence, 200 µL of FBS-free culture medium containing 100 mM galactose, 0.1% NaN₃, 10 nM NH₄Cl, 0.8 µM sucrose, 0.2 nM genistein and 0.4 nM amiloride was incubated with the cells for 2 h respectively, which was followed by adding various FITC-labeled formulations in the presence of different inhibitors. After another 2 h, the cells were again treated in the above-mentioned process and analyzed by flow cytometry.

In vitro cytotoxicity and cell apoptosis

The cytotoxicity of Gal(oct)-C-MEs against HepG2 cells was investigated using conventional MTT method. C-MEs (without galactose ligand) and coix seed oil-MEs (without coixan and tumor ligand) were also used as control groups. Briefly, HepG2 cells were planted in 96-well plates at 5.0×10^3 per well. After incubation for 24 h, the medium was removed, which was followed by addition of various formulations. After treatment for another 24 h, the cells in each well were stained with 10 µL of MTT (0.5 mg/mL) PBS solution at 37°C for 4 h. The culture medium was replaced with 150 µL of dimethyl sulfoxide and the absorbance of the dissolved

blue formazan crystals in each well was measured at 492 nm using an enzyme-linked immunosorbent assay (Thermo Fisher Scientific Inc.). The cell viability was calculated as an absorbance ratio of the tested groups to the negative control group. The half-maximal inhibitory concentration (IC₅₀) was calculated using Statistical Package for the Social Sciences 18.0 (SPSS, Inc., Chicago, IL, USA) software.

We have previously validated the strong apoptosis-inducing ability of coix seed oil-based MEs in human lung tumor (A-549) cell model.¹⁷ To investigate the combined effect of galactose ligand modification and coix polysaccharide incorporation, the cell apoptosis after treatment with various formulations was studied by flow cytometry using Annexin V-PE apoptosis detection kit. In brief, 1.0×10^5 HepG2 cells/well were seeded into 24-well plates and allowed to grow until they reached 80% confluence. Next, the coix seed oil concentration of various formulations including Gal(oct)-C-MEs, C-MEs and coix seed oil-MEs were adjusted as 160 µg/mL, respectively. After incubation for 12 h, the cells were trypsinized by ethylenediaminetetraacetic acid-free pancreatin, rinsed with ice-cold PBS thrice and resuspended in 500 µL of binding buffer successively, which was followed by adding 5 µL of Annexin V-PE and equivalent 7-AAD. At the end of the staining for 15 min, the apoptotic induction was evaluated immediately by flow cytometry (Guava 6HT, Merck Millipore).

In vivo imaging

In our previous studies, stearate galactose-modified C-MEs were capable of accumulation in tumor sites in HepG2 xenograft nude mice models.¹⁵ In this study, to validate that galactose ester with the medium length of carbon chain had a better tumor-targeting ability than stearate galactose ligand, we investigated the biodistribution of Gal(oct)-C-MEs through encapsulating Cy5 (a near-infrared dye) using in vivo near-infrared imaging system (Caliper, Hopkinton, MA, USA). HepG2 xenograft nude mice models were built as described in our previous paper.¹⁵ When the tumor volume reached about 300 mm³, the mice were intragastrically administered with different formulations, including free Cy5, Cy5-labeled C-MEs (Cy5/C-MEs) and Cy5-labeled Gal(oct)-C-MEs (Cy5/Gal(oct)-C-MEs) at a Cy5 dose of 250 µg/kg. The NIR images were observed at determined intervals post-intragastric administration by in vivo imaging system equipped with an excitation band pass filter at 630 nm and an emission filter at 700 nm. At 48 h posttreatment, the mice were sacrificed and tumors were excised. The ex vivo fluorescent images of the tumors were also detected qualitatively

and quantitatively. Besides, Cy5 formulation-treated rats (220–250 g) were also used to investigate the preliminary pharmacokinetic property. The blood samples were collected at determined intervals, and the plasma was obtained by low temperature centrifugation (1,000 rpm × 3 min). The fluorescence was measured by microplate reader (Varioskan Flash, Thermo Fisher Scientific Inc.).

Antitumor efficacy in vivo

Fifty male BALB/c mice (22–25 g) bearing HepG2 tumor xenograft were used in antitumor efficacy study. The animal experiments were carried out in accordance with the protocol approved by the animal ethics committee of Nanjing University of Chinese Medicine (Nanjing, People's Republic of China). When the tumor volume reached about 80 mm³, the mice were randomly separated into five groups and treated with Gal(oct)-C-MEs, C-MEs and coix seed oil-MEs intragastrically each day for 14 days at a coix seed oil dose of 2.5 g/kg/day. Saline and Kanglaite injection (commercial formulation of coix seed oil, Kanglaite Pharmacy Inc., Zhejiang, China) were used as a negative and positive control, respectively. The volumes of the tumor and the body weight of each mouse were monitored every day. The tumor volume (*V*) was calculated using the formula: $V = \text{longitudinal } (L) \times \text{transverse } (W)^2 / 2$. All mice were sacrificed at the end of the treatment, which was followed by weighing the tumor tissues and harvesting various organs. Hematoxylin and eosin staining was used to evaluate the toxicity of treatment against organs through embedding the sections of 5 μm thickness in paraffin and observing by optical microscope.

Safety evaluation

Hematologic toxicity, acute liver–kidney damage and immune suppression are commonly found in anticancer therapy. In this study, we measured the above-mentioned indices through collecting the blood of mice treated with various formulations. Specifically, 300 μL of blood sample was collected from the tail vein at 24 h after the last administration. Thereafter, 50 μL of whole blood was used for blood routine analysis and the remaining sample was allowed to coagulate to obtain serum by centrifuging the clotted blood. Several indices representing the functions of liver and kidney, such as aspartate aminotransferase, alanine aminotransferase and blood urea nitrogen, were detected by blood biochemical analyzer (LH 750, Beckman Coulter). Likewise, the serum immune indices were determined by using enzyme-linked immunosorbent assay kits for interleukin-6 and tumor

necrosis factor-α (enzyme linked Biological Technology Co., Ltd., Shanghai, People's Republic of China).

Statistical analysis

Data are presented as the mean ± standard deviation (SD). Statistical significance of data was determined using Student's *t*-test with **P* < 0.05 as statistical significance and ***P* < 0.01 as extreme statistical significance.

Results and discussion

Characterization of octanoyl galactose ester

Gal(oct) was synthesized by conjugation of galactose (hydroxyl group) and vinyl *n*-octanoate (acyl group) in the presence of Novozym 435 immobilized lipase (illustrated in Figure 2A). Note that an aqueous environment could result in a change in the conformation of Novozym 435 lipase, and thereby reduce the yield of product. Therefore, the solvent and reaction system were kept away from any trace of moisture.¹⁹ As shown in Figure 2B, the molecular weight of Gal(oct) was detected as 307.2941 by HRMS. According to the results of FTIR (Figure 2C), specific carbonyl stretch of ester was observed at 1,705.94 cm⁻¹, which was ascribed to the newly generated bond of Gal(oct). Besides, a broad absorption band at 3,366.61 cm⁻¹ was also found, which represented the O–H stretch of substantial hydroxyl group in galactose. Likewise, the obvious absorption peaks at 2,923 and 2,849.96 cm⁻¹ could be attributed to the aliphatic C–H stretching vibrations of octanoate. The chemical structure of Gal(oct) was further confirmed through the proton nuclear magnetic resonance spectra (¹H NMR). As shown in Figure 2D, the characteristic peaks around 4.85 ppm representing the double bond hydrogen of vinyl group were not found, suggesting that the vinyl groups were substituted by galactose. In addition, the aliphatic chain (δ = 0.89–2.32 ppm) and the galactose segment (δ = 3.51–4.49 and 5.41 ppm) were observed, validating the chemical structure of Gal(oct). In our previous studies, we also synthesized a series of galactose esters with different carbon chain lengths, such as stearyl, butyryl and acetyl galactose ester.

Previously, we synthesized a series of galactose esters with different aliphatic chains, including stearyl, butyryl and acetyl segments. The preliminary findings suggested that galactose ester with a medium carbon chain length (Gal(oct)) displayed the most obvious HepG2 cell/tumor affinity among all the synthesized galactose ester in cellular uptake or in vivo tumor targeting all tumor-targeting ligands. The potential explanation for such a phenomenon

Figure 2 Preparation and characterization of Gal(oct).

Notes: (A) Synthetic pathway of Gal(oct). (B) High-resolution mass spectrum analysis, (C) FTIR spectra and (D) ^1H NMR spectra of Gal(oct).

Abbreviations: FTIR, Fourier transform infrared; Gal(oct), octanoyl galactose ester; ^1H NMR, hydrogen spectrum nuclear magnetic resonance.

is that the length of the carbon chain determines the hydrophilic–lipophilic balance (HLB) of galactose ester. Stearoyl galactose (long chain) might be covered by the coixan shell outside the microemulsion because of the strong hydrophobicity. Conversely, butyryl or acetyl galactose (short chain) is difficult to coat stably on the surface of the microemulsions due to the relatively strong hydrophilicity. In view of this, Gal(oct) with medium chain length was used in further studies.

Preparation and characterization of microemulsions

Gal(oct)-C-MEs and C-MEs were prepared by simple operation and a reliable technology according to our previous reported method.^{15,16} As shown in Figure 3A, the average particle size and zeta potential of Gal(oct)-C-MEs at pH 7.4 were approximately 55 nm and -5.8 mV, respectively. With a decrease in pH, no significant change was found in the size and surface potential, which suggests that Gal(oct)-C-MEs have acceptable stability in different pH environments. There was no obvious alternation in the size and potential of microemulsion before and after modification with galactose ester. However, the particle size and zeta potential of coix oil-MEs reduced significantly than those of C-MEs,

indicating that coixan coated outside the particles increased the size of microemulsions and shielded the partial negative charge, which might be helpful to decrease the adsorption by serum protein and prolong the blood circulation time.²⁰ In order to investigate the influence of coixan and Gal(oct), the morphology of various microemulsions was also determined (Figure 3B). All test samples displayed as spherical particles with around 50 nm, which was essentially in agreement with the results of dynamic light scattering analysis. In addition, we also investigated the *in vitro* release profile of microemulsions using DiI as a fluorescence probe. As shown in Figure 3C, approximately 30% of DiI was released from DiI-labeled Gal(oct)-C-MEs (DiI/Gal(oct)-C-MEs) and DiI-labeled C-MEs (DiI/C-MEs) at 24 h post-incubation by using dialysis method. In contrast, the accumulative release amount of DiI was detected as only 15% in DiI-labeled coix seed oil-MEs (DiI/coix seed oil-MEs). It suggests that the modification of Gal(oct) had no influence on the release behavior on Gal(oct)-C-MEs, but incorporation of coixan seemed to promote the release rate of drugs. The storage stability and pH tolerance tests were performed through observing the transmittance. As displayed in Figure 3D and E, the clarity of the numbers written behind the bottles represented the stability of Gal(oct)-C-MEs. The results suggest

Figure 3 Characterization of different microemulsions.

Notes: (A) Size and zeta potential of microemulsions under various pH environments. (B) Morphologic evaluation studied by transmission electron microscopy. 1 represents Gal(oct)-C-MEs, 2 represents Gal(oct)-coix seed oil-MEs, 3 represents C-MEs and 4 represents coix seed oil-MEs. The scale bar is 50 nm. (C) Release profile of Dil-labeled microemulsion under phosphate-buffered saline of pH 7.4 ($n=3$, $**P<0.01$ vs Dil/Gal(oct)-C-MEs). (D) Stability of Gal(oct)-C-MEs evaluated by observing the clarity from day 1 to day 7. (E) Stability of Gal(oct)-C-MEs (50-fold dilution, pH 2–8) evaluated by observing the clarity within 24 h.

Abbreviations: C-MEs, coix seed component-based microemulsions; Gal(oct)-C-MEs, octanoyl galactose ester-modified microemulsion system self-assembled by coix seed components.

that the Gal(oct)-C-MEs was stable within 5 days or under pH environment of >5.0 .

Cellular uptake

We have previously validated that C-MEs modified with stearate galactose ester could significantly increase the endocytosis of HepG2 cells.¹⁵ In the synthesis of various galactose esters, we found that different aliphatic chains were closely related to the HLB, and thereby determined the compatibility of the tumor-targeted ligand with the microemulsions. Due to the appropriate HLB, Gal(oct) with a medium length chain was assumed to further enhance the cellular uptake of microemulsions. To validate the hypothesis, the internalization of various microemulsions was investigated qualitatively and quantitatively using FITC as a fluorescence

probe. As depicted in Figure 4A, the cells treated with FITC-Gal(oct)-C-MEs displayed overwhelming green fluorescence among all the groups. Comparison between FITC-Gal(oct)-C-MEs and FITC-Gal(oct)-coix oil-MEs showed that the introduction of coixan also synergistically increased the endocytosis. Notably, the cellular uptake of FITC-Gal(oct)-C-MEs sharply decreased when the cells were pretreated with 100 mM galactose, suggesting that the promotion of internalization was mainly contributed by modification of galactose ester.²¹

The fluorescence signal of HepG2 cells treated with various formulations was analyzed by flow cytometry. As shown in Figure 4B, the fluorescence intensity of tumor cells was approximately 400 after treatment with FITC-Gal(oct)-C-MEs, which was 2.28-fold higher than FITC-C-MEs.

Figure 4 HepG2 cellular uptake studies.

Notes: (A) Fluorescence images of HepG2 cells after incubation with various microemulsions at 37°C for 2 h. 1 represents FITC, 2 represents FITC-coix oil-MEs, 3 represents FITC-C-MEs, 4 represents FITC-Gal(oct)-C-MEs, 5 represents FITC-Gal(oct)-coix seed oil-MEs and 6 represents FITC-Gal(oct)-C-MEs with 100 mM free galactose. The scale bar is 50 μ m. (B) Fluorescence intensity of internalized FITC formulations (n=3, ** P <0.01 vs FITC-Gal(oct)-C-MEs). (C) Mechanism of cellular uptake of FITC-Gal(oct)-C-MEs by HepG2 cells (n=3, ** P <0.01 vs control).

Abbreviations: C-MEs, coix seed component-based microemulsions; FITC, fluorescein isothiocyanate; Gal(oct)-C-MEs, octanoyl galactose ester-modified microemulsion system self-assembled by coix seed components.

Compared with FITC-Gal(ste)-C-MEs,¹⁵ modification of octanoyl galactose ester showed an obvious improvement in the cellular uptake of C-MEs, indicating that galactose ester with medium length chain had significant advantage over that with long length chain in cellular uptake. Besides,

the fluorescence intensity of FITC-Gal(oct)-coix oil-MEs was 1.4-fold lower than that of FITC-Gal(oct)-C-MEs, further validating that coixan and galactose ester synergistically enhanced internalization. The internalization mechanism of Gal(oct)-C-MEs was studied using

various specific inhibitors or treatment, such as $4^{\circ}\text{C}/\text{NaN}_3$ (energy inhibitor), NH_4Cl (lyso-endosomers endocytosis inhibitor), sucrose (clathrin-mediated endocytosis inhibitor), genistein (caveolae-mediated endocytosis inhibitor) and amiloride (macropinocytosis inhibitor).²² As displayed in Figure 4C, the cellular uptake greatly reduced when the cells were cultured under low temperature, as well as when treated with NaN_3 , suggesting that Gal(oct)-C-MEs entered the tumor cells in a energy-dependent manner. In addition, the cellular uptake was also inhibited after treatment with NH_4Cl and sucrose, suggesting that Gal(oct)-C-MEs crossed the cell membrane by clathrin-mediated pathway and was consequently entrapped by lyso-endosomers.

In vitro antitumor efficacy

In the cellular uptake studies, Gal(oct)-C-MEs were capable of carrying more active components than C-MEs and Gal(oct)-coix oil-MEs into tumor cells. In this experiment, the cytotoxicity of different formulations was investigated to

figure out whether Gal(oct) could further enhance the cytotoxicity of Gal(oct)-C-MEs against HepG2 cells. As shown in Figure 5A, the IC_{50} of C-MEs was $132.5 \pm 7.3 \mu\text{g/mL}$, which was a 1.5-fold decrease compared with coix oil-MEs, suggesting that coixan-mediated enhancement of cellular uptake promoted killing of tumor cells. With the modification of Gal(oct), the IC_{50} of Gal(oct)-C-MEs reduced up to $46.5 \pm 2.4 \mu\text{g/mL}$, which was a 2.8-fold decrease in comparison with that of C-MEs. In our previous studies, we had verified that C-MEs show 1.8-fold enhancement in cytotoxicity against HepG2 cells due to modification with stearate galactose ester. Obviously, galactose ester with chains of different length notably influenced the cellular behavior of microemulsions, further validating our assumption. Besides, the cytotoxicity of Gal(oct) was also tested to eliminate the effects of galactose ester. As depicted in Figure 5B, no significant inhibition of cell growth was observed after incubation with Gal(oct) at the concentrations ranging from 1.5 to $48 \mu\text{g/mL}$.

Figure 5 In vitro antitumor efficacy.

Notes: (A) Cytotoxicity against HepG2 cells treated with various formulations for 24 h (n=6). (B) Cytotoxicity against HepG2 cells treated with Gal(oct) at different concentrations for 24 h (n=6). (C) Apoptosis of HepG2 cells after incubation with determined formulations at a coix seed oil concentration of $160 \mu\text{g/mL}$ for 12 h. Cells were analyzed by flow cytometry using Annexin V-PE/7-AAD kit.

Abbreviations: C-MEs, coix seed component-based microemulsions; Gal(oct), octanoyl galactose ester; Gal(oct)-C-MEs, octanoyl galactose ester-modified microemulsion system self-assembled by coix seed components; 7-AAD, 7-amino-actinomycin D; Annexin V-PE, phycoerythrin-labeled Annexin V.

Generally, cellular uptake and drug release of nanosize DDS would determine the cell apoptosis within a certain period of treatment.²³ For evaluating the promotion in apoptosis-inducing effect of Gal(oct)-C-MEs by modification with Gal(oct), the cells treated with various microemulsions were analyzed using an Annexin V-PE/7-AAD kit.²⁴ As shown in Figure 5C, both C-MEs and Gal(oct)-C-MEs produced a significantly enhanced apoptosis effect compared with coix oil-MEs, suggesting that coixan and coix oil were capable of apoptosis induction synergistically using such coix component-based microemulsion.^{15–18} Note that 86.3% of HepG2 cells treated with Gal(oct)-C-MEs induced apoptosis, which was 1.2-fold higher than that in the C-MEs group. These findings indicated that the synergistic anticancer effect by rational drug combination and the improved intracellular accumulation by the rational design of tumor-targeted ligand were of great importance in cell apoptosis induction.

Tumor targeting in vivo and pharmacokinetics

To validate our assumption that modification of galactose ester with medium carbon chain was favorable for improving tumor targeting of microemulsions, we evaluated the biodistribution of Gal(oct)-C-MEs using the *in vivo* imaging technique with C-MEs as the control group. Cy5, a commonly used near-infrared dye, was encapsulated into various microemulsions for visualization of distribution *in vivo*.^{25,26} At 8 h post-intragastric administration of free Cy5, the fluorescence signal of HepG2 tumor-bearing mice mainly accumulated in the intestinal tract and was eliminated rapidly from 8 to 24 h. Due to nanoparticle-mediated EPR effect, Cy5/C-MEs presented a potential of tumor targeting after crossing the enterocytes, especially at the initial 4 h. In sharp contrast, Cy5/Gal(oct)-C-MEs displayed the most obvious fluorescence signal in the tumor site, which was retained for 48 h (Figure 6A). For further confirming the accumulation of the tumor, *ex vivo* imaging was observed immediately after harvest of the tumor tissues from HepG2 tumor-bearing mice. As expected, the fluorescence intensity of the tumor tissue excised from Cy5/Gal(oct)-C-MEs-treated mice was 1.9-fold higher than that of Cy5/C-MEs-treated mice (Figure 6B and C), presenting a concrete proof of rationality of Gal(oct) modification.

Prolonged circulation in blood is a critical and inherent merit for orally administrated nanosized vehicle, because particles have more time to accumulate in the tumor region.²⁷ In this experiment, we also evaluated the pharmacokinetics of Cy5/Gal(oct)-C-MEs after intragastric administration by quantifying the Cy5 intensity in plasma. Free Cy5 and Cy5/

C-MEs were taken as references. As shown in Figure 6D, the concentration of Cy5 in all test groups reached the maximum at 1 h post-administration. However, the absorption peak of the two microemulsion groups was 2-fold higher than that of free Cy5, which exhibited an enhancement of microemulsion on oral bioavailability. Logically, there was no obvious difference in the pharmacokinetic behavior between Cy5/Gal(oct)-C-MEs and Cy5/C-MEs, suggesting that modification of Gal(oct) did not influence the oral absorption. These results indicated that the combination strategy of multicomponent microemulsion design and Gal(oct) modification offered a potential for tumor targeting *in vivo* and improved the pharmacokinetic characteristics.

In vivo antitumor efficacy

Oral delivery of coix seed oil and coixan using Gal(oct)-C-MEs could lead to significant accumulation in the tumor sites through the synergistic strategy of Gal(oct) modification and microemulsion formulation. Generally, such a characteristic could also promote the *in vivo* anticancer efficacy and reduce the side effects. In this experiment, the antitumor activity of Gal(oct)-C-MEs was evaluated in BALB/c nude mice bearing HepG2 xenografts, with C-MEs, coix oil-MEs and Kanglaite used as controls.^{28,29} After intragastric administration of various microemulsions for 14 days, inhibition of tumor growth significantly increased compared with the saline-treated group and the coix oil-treated group.³⁰ In this, Gal(oct)-C-MEs presented a remarkable enhancement of retardation of tumor growth in comparison with C-MEs (Figure 7A) and even had similar potential to intraperitoneally administrated Kanglaite. According to our previously reported formula,¹⁵ the inhibition rates of tumor growth by Gal(oct)-C-MEs and Kanglaite were both >74%, which achieved a further improvement in comparison with Gal(ste)-C-MEs. As a orally administrated microemulsion assembled by the bioactive components of coix seed, such a strong anticancer efficacy was obviously connected with Gal(oct) modification, multicomponent combination and microemulsion-based passive tumor targeting. In addition, the time from the end of therapy to reach double the volume of tumor tissues was also used to evaluate the effect after anticancer therapy. As shown in Figure 7B, the tumor of mice treated with C-MEs grew to 2-fold volume within 11 days, which was the longest among all the test groups. It suggests that C-MEs could sustain the effect of tumor growth delay even after ending the treatment. As expected, the weight of the tumor tissues harvested from mice treated with Gal(oct)-C-MEs was obviously lighter than in other treatments (Figure 7C), which was consistent

Figure 6 Evaluation of Gal(oct)-C-MEs in vivo tumor targeting using Cy5 as a fluorescence probe.

Notes: (A) Biodistribution of HepG2 tumor-bearing nude mice intragastrically administered with free Cy5, Cy5/C-MEs and Cy5/Gal(oct)-C-MEs at determined intervals. (B) Ex vivo imaging of the tumor excised from HepG2 tumor-bearing mice at 48 h posttreatment. (C) Quantitation of average radiant efficiency of the harvested tumor tissues (n=3, **P<0.01 vs Cy5/C-MEs). (D) The changes in Cy5 concentration in the plasma collected within 24 h after intragastric administration in rats (n=3).

Abbreviations: C-MEs, coix seed component-based microemulsions; Gal(oct), octanoyl galactose ester; Gal(oct)-C-MEs, octanoyl galactose ester-modified microemulsion system self-assembled by coix seed components.

with the curve of tumor growth. Furthermore, the survival time of mice after different treatments was also recorded. As depicted in Figure 7D, Gal(oct)-C-MEs-treated group exhibited the longest survival time in HepG2 tumor-bearing mice model among all the formulations (54 days), further offering a concrete proof of our hypothesis.

Safety evaluation

The main pharmacologically active components of Gal(oct)-C-MEs were extracted from coix seed, which did

not exert antitumor effects powerfully like several other chemotherapeutics such as paclitaxol and doxorubicin. In order to evaluate the systemic toxicity against mice treated with Gal(oct)-C-MEs, various important indices of safety including body weight, liver/spleen index, the function of liver and kidney, pathology of normal tissues, hematology and preliminary immune function were thoroughly investigated during and after the anticancer treatment. As shown in Figure 8A, the body weight of mice did not significantly decrease after different therapies, indicating a low systemic

Figure 7 Antitumor efficacy study in vivo.

Notes: (A) Inhibition of tumor growth in HepG2 tumor-bearing nude mice after various treatments (n=8, ** $P < 0.01$, * $P < 0.05$). The arrows from day 8 to day 21 indicate the therapy time. (B) The time taken for the volume of tumor tissues to double after ending the therapy (n=8). (C) The weight of the tumor tissues harvested from the mice treated with various formulations (n=8, ** $P < 0.01$). (D) The survival curve of model mice within 54 days.

Abbreviations: C-MEs, coix seed component-based microemulsions; Gal(oct), octanoyl galactose ester; Gal(oct)-C-MEs, octanoyl galactose ester-modified microemulsion system self-assembled by coix seed components.

Figure 8 (Continued)

Figure 8 Safety evaluation.

Notes: (A) Changes in the body weight of mice within 29 days. (B) The liver and spleen index of mice after treatment for 72 h (n=4). The acute damage of (C) kidney and (D) liver at 72 h after the last injection (n=4). (E) The morphology of liver, kidney and tumor tissues of mice after treatment with different formulations, as found with hematoxylin and eosin staining. The scale bar is 20 μ m.

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; C-MEs, coix seed component-based microemulsions; Gal(oct), octanoyl galactose ester; Gal(oct)-C-MEs, octanoyl galactose ester-modified microemulsion system self-assembled by coix seed components.

side effect. The liver and spleen were collected at 72 h posttreatment to evaluate the influence of treatment on the important immune organs. The liver and spleen index showed no obvious difference among all the groups (Figure 8B), suggesting low toxicity of Gal(oct)-C-MEs against the immune organs. Acute damage of liver and kidney commonly occurred in the conventional chemotherapy.^{24,31} However, treatment with Gal(oct)-C-MEs did not bring about any alternation in the liver enzymes (alanine aminotransferase and

aspartate aminotransferase) and acute renal lesion indicators (blood urea nitrogen; Figure 8C and D). The histopathology of kidney, liver and tumor tissues was evaluated through hematoxylin and eosin staining. Oral administration of Gal(oct)-C-MEs did not result in solid lesion or abnormality in the liver and kidney, but led to significant remission in the section of tumor tissues (Figure 8E).

In addition, the hematology of mice after therapy for 24 h was investigated through routine blood analysis.

Table 1 Evaluation of WBC, RBC, HGB and PLT in the serum of mice treated with various formulations (n=5)

Formulation	WBC ($10^9/L$)	RBC ($10^{12}/L$)	HGB (g/L)	PLT ($10^9/L$)
Saline	12.56±3.24	10.28±1.26	111.02±10.26	955.30±107.25 ^a
Coix oil-MEs	16.07±2.18 ^{a,b}	12.03±1.79	160.54±21.92 ^{a,b}	1,035.45±128.81
C-MEs	17.63±1.41 ^{a,b}	9.84±1.66	137.63±25.53 ^{a,b}	1,419.15±66.51 ^b
Gal(oct)-C-MEs	17.56±3.13 ^{a,b}	8.51±1.59 ^a	110.06±11.02 ^a	1,540.63±248.84 ^{a,b}
Kanglaite® injection	12.92±4.25	10.87±1.84	133.51±13.44 ^b	1,261.27±234.98 ^b

Notes: ^aP<0.05 vs Kanglaite injection; ^bP<0.05 vs saline.

Abbreviations: C-MEs, coix seed component-based microemulsions; Gal(oct)-C-MEs, octanoyl galactose ester-modified microemulsion system self-assembled by coix seed components; HGB, hemoglobin; PLT, platelet; RBC, red blood cell; WBC, white blood cell.

As shown in Table 1, Gal(oct)-C-MEs administration brought about a significant increase in white blood cells and platelets, offering a feasibility of combination therapy with chemotherapeutics.^{17,32,33} As for the influence on the immune function, the concentrations of cytokines were also detected. As shown in Table 2, treatment with microemulsion did not reduce the serum concentration of tumor necrosis factor- α and interleukin-6 significantly. All the data suggest that Gal(oct)-C-ME could be used as a safe nanosized DDS in vivo which acts by improved tumor targeting and as a highly effective anticancer vehicle through rational drug combination.

Conclusion

We developed a octanoyl galactose ester-modified coix seed multicomponent microemulsion system (Gal(oct)-C-MEs), which achieved significant enhancement of HepG2 cellular uptake, remarkable improvement in the cytotoxicity and obvious promotion of the induction of cell apoptosis. In addition, orally administrated Gal(oct)-C-MEs could prolong the intestinal retention, elevate the oral bioavailability and realize tumor-specific distribution. Importantly, Gal(oct)-C-MEs displayed an overwhelming antihepatic efficacy in the xenograft tumor mice models among all the test groups. These findings suggested that Gal(oct)-C-MEs

could be used as an efficient oral delivery system for hepatoma therapy.

Acknowledgments

This work was carried out with the financial support of the National Natural Science Foundation (81373979 and 81503264), the key projects of Jiangsu Provincial Administration of Traditional Chinese Medicine (ZD201509), and the Jiangsu Provincial Natural Science Foundation (BK20141038 and BK 20141058).

Disclosure

The authors report no conflicts of interest in this work.

References

- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin*. 2011;61(2):69–90.
- Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. *J Clin Gastroenterol*. 2013;47 Suppl:S2–S6.
- Shah SM, Goel PN, Jain AS, et al. Liposomes for targeting hepatocellular carcinoma: use of conjugated arabinogalactan as targeting ligand. *Int J Pharm*. 2014;477(1–2):128–139.
- Wang J, Zhang Z, Wang X, Wu W, Jiang X. Size- and pathotropism-driven targeting and washout-resistant effects of boronic acid-rich protein nanoparticles for liver cancer regression. *J Control Release*. 2013;168(1):1–9.
- Mo R, Jiang T, Gu Z. Recent progress in multidrug delivery to cancer cells by liposomes. *Nanomedicine (Lond)*. 2014;9(8):1117–1120.
- Deshpande PP, Biswas S, Torchilin VP. Current trends in the use of liposomes for tumor targeting. *Nanomedicine (Lond)*. 2013;8(9):1509–1528.
- Krais A, Wortmann L, Hermanns L, et al. Targeted uptake of folic acid-functionalized iron oxide nanoparticles by ovarian cancer cells in the presence but not in the absence of serum. *Nanomedicine*. 2014;10(7):1421–1431.
- Song S, Chen F, Qi H, et al. Multifunctional tumor-targeting nanocarriers based on hyaluronic acid-mediated and pH-sensitive properties for efficient delivery of docetaxel. *Pharm Res*. 2014;31(4):1032–1045.
- Zeng X, Tao W, Mei L, Huang L, Tan C, Feng SS. Cholic acid-functionalized nanoparticles of star-shaped PLGA-vitamin E TPGS copolymer for docetaxel delivery to cervical cancer. *Biomaterials*. 2013;34(25):6058–6067.
- Ding J, Xiao C, Li Y, et al. Efficacious hepatoma-targeted nanomedicine self-assembled from galactopeptide and doxorubicin driven by two-stage physical interactions. *J Control Release*. 2013;169(3):193–203.

Table 2 Concentrations of TNF- α and IL-6 in the serum of mice after treatment with various formulations (n=5)

Formulation	TNF- α (pg/mL)	IL-6 (pg/mL)
Saline	34.15±1.06	24.23±2.35
Coix oil-MEs	55.90±2.12 ^{a,b}	23.91±1.36
C-MEs	45.90±7.05 ^a	25.05±1.12
Gal(oct)-C-MEs	48.40±5.63 ^a	24.87±0.65
Kanglaite® injection	48.60±3.67 ^a	25.20±2.01

Notes: ^aP<0.05 vs saline; ^bP<0.05 vs Kanglaite injection.

Abbreviations: C-MEs, coix seed component-based microemulsions; Gal(oct)-C-MEs, octanoyl galactose ester-modified microemulsion system self-assembled by coix seed components; IL, interleukin; TNF- α , tumor necrosis factor α .

11. Chen W, Zou Y, Meng F, et al. Glyco-nanoparticles with sheddable saccharide shells: a unique and potent platform for hepatoma-targeting delivery of anticancer drugs. *Biomacromolecules*. 2014;15(3):900–907.
12. Yu CY, Wang YM, Li NM, et al. In vitro and in vivo evaluation of pectin-based nanoparticles for hepatocellular carcinoma drug chemotherapy. *Mol Pharm*. 2014;11(2):638–644.
13. Zhu D, Tao W, Zhang H, et al. Docetaxel (DTX)-loaded polydopamine-modified TPGS-PLA nanoparticles as a targeted drug delivery system for the treatment of liver cancer. *Acta Biomater*. 2016;30:144–154.
14. Wu DQ, Lu B, Chang C, et al. Galactosylated fluorescent labeled micelles as a liver targeting drug carrier. *Biomaterials*. 2009;30(7):1363–1371.
15. Qu D, Sun W, Liu M, Liu Y, Zhou J, Chen Y. Bitargeted microemulsions based on coix seed ingredients for enhanced hepatic tumor delivery and synergistic therapy. *Int J Pharm*. 2016;503(1–2):90–101.
16. Liu MJ, Qu D, Chen Y, Liu CY, Liu YP, Ding XF. Preparation of novel butyryl galactose ester-modified coix component microemulsions and evaluation on hepatoma-targeting in vitro and in vivo. *Drug Deliv*. 2016;23(9):3444–3451.
17. Qu D, Ma Y, Sun W, et al. Microemulsion-based synergistic dual-drug co-delivery system for enhanced apoptosis of tumor cells. *Int J Nanomed*. 2015;10:1173–1187.
18. Qu D, Lin H, Zhang C, Xue J, Zhang C. In vitro evaluation on novel modified chitosan for targeted antitumor drug delivery. *Carbohydr Polym*. 2013;92(1):545–554.
19. Lee MY, Dordick JS. Enzyme activation for nonaqueous media. *Curr Opin Biotechnol*. 2002;13(4):376–384.
20. De Luca MA, Lai F, Corrias F, et al. Lactoferrin- and antitransferrin-modified liposomes for brain targeting of the NK3 receptor agonist senktide: preparation and in vivo evaluation. *Int J Pharm*. 2015;479(1):129–137.
21. Mou Q, Ma Y, Zhu X, Yan D. A small molecule nanodrug consisting of amphiphilic targeting ligand-chemotherapy drug conjugate for targeted cancer therapy. *J Control Release*. 2016;230:33–34.
22. Su Z, Xing L, Chen Y, et al. Lactoferrin-modified poly(ethylene glycol)-grafted BSA nanoparticles as dual-targeting carrier for treating brain gliomas. *Mol Pharm*. 2014;11(6):1823–1834.
23. Mo R, Jiang T, DiSanto R, Tai W, Gu Z. ATP-triggered anticancer drug delivery. *Nat Commun*. 2014;5:3364.
24. Huang X, Li L, Liu T, et al. The shape effect of mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo. *ACS Nano*. 2011;5(7):5390–5399.
25. Chen G, Jaskula-Sztul R, Harrison A, et al. KE108-conjugated unimolecular micelles loaded with a novel HDAC inhibitor thailandepsin-A for targeted neuroendocrine cancer therapy. *Biomaterials*. 2016;97:22–33.
26. Saurabh S, Perez AM, Comerici CJ, et al. Super-resolution imaging of live bacteria cells using a genetically directed, highly photostable fluoromodule. *J Am Chem Soc*. 2016;138(33):10398–10401.
27. Pridgen EM, Alexis F, Kuo TT, et al. Transepithelial transport of Fc-targeted nanoparticles by the neonatal fc receptor for oral delivery. *Sci Transl Med*. 2013;5(213):213ra167.
28. Wang Y, Dou L, He H, Zhang Y, Shen Q. Multifunctional nanoparticles as nano-carrier for vincristine sulfate delivery to overcome tumor multidrug resistanc. *Mol Pharm*. 2014;11(3):885–894.
29. Ju C, Mo R, Xue J, et al. Sequential intra-intercellular nanoparticle delivery system for deep tumor penetration. *Angew Chem Int Ed Engl*. 2014;53(24):6253–6258.
30. Qu D, He J, Liu C, Zhou J, Chen Y. Triterpene-loaded microemulsion using Coix lacryma-jobi seed extract as oil phase for enhanced antitumor efficacy: preparation and in vivo evaluation. *Int J Nanomed*. 2014;9:109–119.
31. Charoensuk L, Pinlaor P, Wanichwecharungruang S, et al. Nanoencapsulated curcumin and praziquantel treatment reduces periductal fibrosis and attenuates bile canalicular abnormalities in *Opisthorchis viverrini*-infected hamsters. *Nanomedicine*. 2016;12(1):21–32.
32. Zhou M, Zhang X, Yu C, Nan X, Chen X, Zhang X. Shape regulated anticancer activities and systematic toxicities of drug nanocrystals in vivo. *Nanomedicine*. 2016;12(1):181–189.
33. Kretzer IF, Maria DA, Guido MC, Contente TC, Maranhão RC. Simvastatin increases the antineoplastic actions of paclitaxel carried in lipid nanoemulsions in melanoma-bearing mice. *Int J Nanomedicine*. 2016;11:885–904.

International Journal of Nanomedicine

Publish your work in this journal

The International Journal of Nanomedicine is an international, peer-reviewed journal focusing on the application of nanotechnology in diagnostics, therapeutics, and drug delivery systems throughout the biomedical field. This journal is indexed on PubMed Central, MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine,

Submit your manuscript here: <http://www.dovepress.com/international-journal-of-nanomedicine-journal>

Dovepress

Journal Citation Reports/Science Edition, EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.